|
USC Norris Comprehensive Cancer Center (Core) Grant
|
2P30CA014089-41
|
$6,354,897
|
$381,294
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-41S1
|
$59,999
|
$3,600
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
USC Norris Comprehensive Cancer Center (Core) Grant
|
3P30CA014089-41S2
|
$37,500
|
$2,250
|
GRUBER, STEPHEN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Tumor Microenvironment in Cancer Progression
|
ZIA BC 011332
|
$353,472
|
$35,347
|
Kaplan, Rosandra
|
CCR (NCI)
|
|
Transcriptional CDKs as therapeutic targets in MYC-dependent cancers
|
1R01CA197336-01A1
|
$407,748
|
$407,748
|
GEORGE, RANI
|
DANA-FARBER CANCER INST
|
|
Training Physician Scientists in Pediatric Oncology
|
2T32CA009659-21A1
|
$64,768
|
$32,384
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
The Role of LIN28B Signaling in Mediating the Oncogenic Phenotype in Neuroblastoma
|
1K08CA194162-01A1
|
$168,264
|
$168,264
|
SCHNEPP, ROBERT
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
3R01CA166749-04S1
|
$13,734
|
$13,734
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Role of Growth Factor Receptor Trafficking in Tumorigenesis
|
4R01CA166749-04
|
$318,913
|
$318,913
|
ZAGE, PETER
|
BAYLOR COLLEGE OF MEDICINE
|
|
THE INITIATION AND REGULATION OF INFLAMMATION IN NEUROBLASTOMA
|
2R01CA116548-11A1
|
$249,637
|
$249,637
|
METELITSA, LEONID
|
BAYLOR COLLEGE OF MEDICINE
|
|
The Genetic Basis of Neuroblastoma Tumorigenesis
|
4R01CA124709-09
|
$614,290
|
$614,290
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting the G-CSF/STAT3 signaling pathway in neuroblastoma cancer stem cells
|
5R01CA174808-03
|
$326,348
|
$326,348
|
SHOHET, JASON
|
BAYLOR COLLEGE OF MEDICINE
|
|
Targeting Oncogenic ALK Signaling in Neuroblastoma
|
5R01CA140198-08
|
$374,344
|
$374,344
|
MOSSE, YAEL
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Targeting nutrient-sensing pathways in cancer
|
1K22CA201103-01
|
$190,640
|
$190,640
|
LAZARUS, MICHAEL
|
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
|
|
Targeting Neuroblastoma with armed T cells
|
7R01CA182526-03
|
$822,924
|
$822,924
|
LUM, LAWRENCE
|
UNIVERSITY OF VIRGINIA
|
|
Systems Biology of Tumor Progression and Drug Resistance
|
4U01CA168426-05
|
$1,238,106
|
$1,238,106
|
CALIFANO, ANDREA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Structural Variation in Neuroblastoma
|
1R01CA204974-01A1
|
$384,300
|
$384,300
|
DISKIN, SHARON
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Sphingosine-1-Phosphate Pathway Based Therapy for Neuroblastoma
|
4R01CA168903-05
|
$345,402
|
$345,402
|
FERRER, FERNANDO
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
Second generation MIBG analogs that cotarget DNA for high risk neuroblastoma
|
1R21CA187548-01A1
|
$196,403
|
$196,403
|
BARANOWSKA-KORTYLEWICZ, JANINA
|
UNIVERSITY OF NEBRASKA MEDICAL CENTER
|
|
Role of Trk Receptors in the Development and Function of Non-neuronal Structures
|
ZIA BC 010391
|
$497,160
|
$49,716
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of Neurotrophins in the Development of the Mammalian Nervous System
|
ZIA BC 010390
|
$509,589
|
$101,918
|
Tessarollo, Lino
|
CCR (NCI)
|
|
Role of LMO1 in Neuroblastoma Initiation and Maintenance
|
5R01CA180692-02
|
$606,838
|
$606,838
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Research Management and Support
|
RMS ES 2016
|
$320,501,735
|
$101,000
|
N/A
|
National Institutes of Health
|
|
Regulation of MDM2 auto-ubiquitination and molecular targeting
|
4R01CA123490-09
|
$251,191
|
$62,798
|
ZHOU, MUXIANG
|
EMORY UNIVERSITY
|
|
Regulation of Differentiation of Pediatric Embryonal Tumors- Neuroblastoma
|
ZIA BC 010788
|
$597,142
|
$447,857
|
Thiele, Carol
|
CCR (NCI)
|
|
Pretherapy 124I-MIBG Dosimetry for Planning 131I-MIBG Neuroblastoma Therapy
|
4R01CA154561-06
|
$350,001
|
$350,001
|
SEO, YOUNGHO
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Prenatal stress and neuroblastoma development - is there a link?
|
5R21CA198698-02
|
$169,106
|
$169,106
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
Plasminogen activator inhibitor-1 in tumor progression and metastasis
|
4R01CA129377-09
|
$239,246
|
$239,246
|
DECLERCK, YVES
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Pharmacokinetics and pharmacogenomics for 13-cis retinoic acid in neuroblastoma
|
4R01CA168699-04
|
$284,060
|
$284,060
|
KANG, MIN
|
TEXAS TECH UNIVERSITY HEALTH SCIS CENTER
|
|
Pediatric Preclinical Testing Consortium
|
5U01CA199287-02
|
$357,000
|
$357,000
|
MARIS, JOHN
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Pediatric Oncology Branch Clinical Care and Education
|
ZIE BC 011516
|
$3,340,699
|
$167,035
|
Glod, John
|
CCR (NCI)
|
|
Pathophysiologic Consequences of Neurotrophin Activation of Trk in Neuroblastoma
|
ZIA BC 010789
|
$321,538
|
$289,384
|
Thiele, Carol
|
CCR (NCI)
|
|
Pathogenic Roles of SHP2 & PTPRD Tyrosine Phosphatases in High-Risk Neuroblastoma
|
5R00CA178189-04
|
$249,000
|
$249,000
|
ZHU, SHIZHEN
|
MAYO CLINIC ROCHESTER
|
|
Optimizing 131I-mIBG Therapy for Children with Advanced Neuroblastoma
|
5R01CA172067-05
|
$363,426
|
$363,426
|
DUBOIS, STEVEN
|
DANA-FARBER CANCER INST
|
|
Neuropeptide Y (NPY) as a hypoxia-driven metastatic factor
|
5R01CA197964-02
|
$351,644
|
$175,822
|
KITLINSKA, JOANNA
|
GEORGETOWN UNIVERSITY
|
|
MYCN-induced calcium and magnesium signaling regulates Neuroblastoma progression
|
4K01CA154758-05
|
$134,922
|
$134,922
|
KOOMOA, DANA-LYNN
|
UNIVERSITY OF HAWAII AT HILO
|
|
MYC--Transcription and Apoptosis
|
5R01CA051497-25
|
$733,273
|
$366,637
|
DANG, CHI
|
UNIVERSITY OF PENNSYLVANIA
|
|
Murine Neuroblastoma Models for Preclinical Therapeutics
|
4R01CA102321-13
|
$261,089
|
$261,089
|
WEISS, WILLIAM
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Molecular Diagnostics for Risk Stratification and Monitoring of Neuroblastoma
|
5R01CA182633-03
|
$665,155
|
$665,155
|
ASGHARZADEH, SHAHAB
|
CHILDREN'S HOSPITAL OF LOS ANGELES
|
|
Molecular determinants of PARP inhibitor sensitivity in 11q-deleted malignancy
|
5R21CA181417-02
|
$219,957
|
$109,979
|
FRANCO, SONIA
|
JOHNS HOPKINS UNIVERSITY
|
|
Molecular Characteristics of Treatment-resistant High-risk Neuroblastoma
|
1R01CA197903-01A1
|
$394,607
|
$394,607
|
ZHONG, JOHN
|
UNIVERSITY OF SOUTHERN CALIFORNIA
|
|
Methods for genomic data with graphical structures
|
4R01CA127334-09
|
$293,687
|
$146,844
|
LEE, HONGZHE
|
UNIVERSITY OF PENNSYLVANIA
|
|
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
|
1R41CA206859-01A1
|
$299,738
|
$149,869
|
DURDEN, DONALD
|
SIGNALRX PHARMACEUTICALS, INC.
|
|
Large-scale Genetic Analyses of Human Cancer
|
4R01CA121113-10
|
$279,212
|
$13,961
|
VELCULESCU, VICTOR
|
JOHNS HOPKINS UNIVERSITY
|
|
Investigating non-coding mechanisms of functional dysregulation in neuroblastoma
|
5F30CA192831-02
|
$30,400
|
$30,400
|
OLDRIDGE, DEREK
|
UNIVERSITY OF PENNSYLVANIA
|
|
Identification of Novel Mutations In Pediatric Cancers
|
ZIA BC 010998
|
$526,915
|
$210,766
|
Khan, Javed
|
CCR (NCI)
|
|
Identification of novel cooperating partners of MYCN in neuroblastoma tumorigenesis
|
1K99CA197484-01A1
|
$160,773
|
$160,773
|
HUANG, MILLER
|
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
|
|
Identification of Genes for Predicting Prognosis in Pediatric Cancers
|
ZIA SC 010366
|
$175,638
|
$87,819
|
Khan, Javed
|
CCR (NCI)
|
|
Hypoxia induces SHMT2 to regulate cellular redox and epigenetics
|
5K99CA184239-02
|
$104,417
|
$104,417
|
YE, JIANGBIN
|
SLOAN-KETTERING INST CAN RESEARCH
|
|
HiTIF Microscopy Core Facility
|
ZIC BC 011567
|
$647,977
|
$129,595
|
Pegoraro, Gianluca
|
CCR (NCI)
|
Total relevant funding to Neuroblastoma for this search: $19,959,764
|